What is the clinical evidence from this study?

Population: Diabetic cardiomyopathy (n=32). Intervention: Azelnidipine vs. Untreated diabetic rats (vehicle). Primary outcome: Maximal rate of left ventricular systolic pressure rise (+dP/dt) (p=<0.05).

November 4, 2011Cardiovascular DiabetologyOpen Access

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis

Q: What are the key findings of this study?

Azelnidipine treatment for 12 weeks significantly improved cardiac contractile dysfunction, restored intracellular calcium homeostasis, and reduced oxidative stress and apoptosis in streptozotocin-diabetic rats.

View Full Paper

Ask AI

Bookmark

Key result

Azelnidipine treatment for 12 weeks significantly improved cardiac contractile dysfunction, restored intracellular calcium homeostasis, and reduced oxidative stress and apoptosis in streptozotocin-diabetic rats.

Why the study?

Does azelnidipine prevent cardiac dysfunction in streptozotocin-diabetic rats?

Population

Adult male Wistar rats with streptozotocin (STZ)-induced diabetes

Comparison

Azelnidipine (AZL) vs Untreated STZ-diabetic rats

Design

Preclinical

Authors

VKVasundhara KainUniversity of South Florida SKSandeep KumarChaudhary Charan Singh Haryana Agricultural University SSSandhya L. SitasawadNational Centre for Cell Science

Discussion

Member takes

Implication

Supports hypothesis of benefit in diabetic rat cardiomyopathy; leaves open translation to human therapy.

Structured PICO

Does azelnidipine prevent cardiac dysfunction in streptozotocin-diabetic rats?

Population

32 adult male Wistar rats with streptozotocin-induced diabetes were treated with azelnidipine for 12 weeks to evaluate its effects on cardiac dysfunction.

Intervention

Azelnidipine (AZL)

Comparator

Untreated STZ-diabetic rats

Outcome

Myocyte contractile dysfunction (peak shortening, time-to-PS, time-to-relengthening, maximal velocity of shortening/relengthening) and intracellular Ca2+ fluorescencesurrogate

Main Result

Absolute Event Rate: 6098.6% vs 3219.3%

p-value: p=<0.05

Azelnidipine prevents cardiac dysfunction in diabetic rats by modulating intracellular calcium handling and reducing oxidative stress and apoptosis.

Limitations

Did not test the effect of known antioxidants in comparison to AZL.
Changes observed after 12 weeks may be due to overall functional improvement rather than direct AZL effects.
Lack of baseline hemodynamic values in the same animals at the start of the study.

Cite This Study

Kain et al. (2011) studied Diabetic cardiomyopathy (n=32). Azelnidipine vs. Untreated diabetic rats (vehicle) was evaluated on Maximal rate of left ventricular systolic pressure rise (+dP/dt) (p=<0.05). Azelnidipine treatment for 12 weeks significantly improved cardiac contractile dysfunction, restored intracellular calcium homeostasis, and reduced oxidative stress and apoptosis in streptozotocin-diabetic rats.

synapsesocial.com/papers/6a63ace750e2b8a4ef6ad0d2 https://doi.org/10.1186/1475-2840-10-97

View Full Paper

Ask AI

Bookmark

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider